BMS Has A Lot Of Ground To Make Up Ahead Of Patent Expiries
Opdivo Has Another Down Quarter
Bristol Myers Squibb is struggling to restore Opdivo’s growth and COVID-19 sales impacts didn’t help in Q1. New indications are coming but new products, like Zeposia, are slow to add significant revenue.
